Background Antipsychotic (AP) drugs are commonly used to manage the behavioural symptoms of dementia. Nevertheless, international (i.e 
Introduction
Over 90 % of people with dementia experience behavioral and psychological symptoms of dementia (BPSD), including aggression, confusion and hallucinations [1] , for which antipsychotics (APs) are commonly prescribed, usually offlabel [2] . Ballard and Waite [3] conducted a systematic review of 18 placebo-controlled randomized controlled trials (RCTs) and found significant but modest improvements in aggression (standardized effect size 0.22) and smaller but significant benefits in psychosis (standardized effect size 0.18) over 6-12 weeks of treatment with risperidone and olanzapine in patients with BPSD. In contrast, according to the same systematic review and a meta-analysis [3, 4] , quetiapine appeared ineffective. In Europe, risperidone is the only AP indicated for the treatment of BPSD (for short-term [B6 weeks] management of severe aggression in dementia if unresponsive to other treatments) [5] . Severe AP-related adverse effects in patients with dementia include pneumonia, stroke and all-cause mortality [6] [7] [8] .
Following a pooled analysis of RCTs in 2004, the European Medicines Agency (EMA) reported an almost twofold increased risk of all-cause mortality and threefold increase in cerebrovascular events in patients with dementia treated with risperidone and olanzapine [9] . Thereafter, a series of safety warnings about AP use in dementia were launched by international/national agencies (Table 1) . Although the initial warnings pertained specifically to the atypical APs risperidone and olanzapine, the regulatory safety warnings were extended to all APs in 2009. During this period, the Alzheimer's Society and the All Party Parliamentary Group on Dementia in England also released high-profile reports targeting inappropriate AP prescribing [10] . A review in 2009 commissioned by the UK Department of Health indicated that unnecessary AP use was potentially leading to an additional 1600 strokes and 1800 deaths in older patients with dementia annually [11] . Following the publication of this report, a proactive initiative was undertaken in England, with the government committing to reducing the use of APs in dementia by two-thirds by 2011. A ministerial working group was established, and the reduction of AP prescribing became a key target of English dementia policy strategies [12] . The Dementia Action Alliance, formed between key stakeholders (government, professional bodies and charities representing people with dementia), launched a call to action on inappropriate AP prescribing in June 2011. Toolkits were produced to support health/social care professionals in using alternative approaches [13] .
The UK Department of Health commissioned the National Dementia and AP Prescribing (DAP) audit, which suggested a reduction in AP prescribing by half between 2008 and 2011 [14] , but participation in the audit was voluntary, leading to potential biases. In contrast, in 2005, the Italian Drug Agency launched an active pharmacovigilance initiative targeted at Italian specialist dementia centers, but no assessment of AP prescribing trends was planned [15] . This activity involved completing a pharmacovigilance datasheet if APs were prescribed to a person with dementia. In Italy, the same warning in 2005 advised physicians to review their patients every 2 months; it also reminded them that the duration of AP use in patients with dementia should not exceed 90 days. Other AP-related initiatives in Italy were oriented more towards advice than direct action compared with UK initiatives, whereas some had a technical-legal and/or a clinical nature. For example, the communication from the Italian Drug agency (Agenzia Italiana del Farmaco [AIFA]) in 2009 reminded prescribers that informed consent is required by law before the first AP is prescribed to a person with dementia. This warning also advised that APs should be used only where strictly needed in patients with dementia. The effectiveness of risk-minimization measures requires careful monitoring through observational studies [16] . The effect of safety warnings on AP prescribing has been investigated in several countries within [17] [18] [19] and outside [20, 21] Europe (Appendix 1; appendices can be found in the Electronic Supplementary Material). The two available Italian studies investigated only short-term effects of the warnings, and one was also limited to a restricted geographic area [22, 23] . No nationwide studies have been conducted in the UK so far, although a study by Guthrie et al. [24] has described AP use after the Medicines and Health Products Regulatory Agency (MHRA) warnings in 2004 and 2009 using data from 87 Scottish general practices.
Given the lack of information on recent trends in the use of APs in Italy and the UK, the aim of this populationbased study was to investigate and compare the short-and long-term effects of the safety warnings issued by international/national drug regulatory agencies on AP prescribing in older people with dementia in the UK and Italy. Given that the DAP audit found a 50 % reduction in the use of APs in dementia patients in the UK between 2008 and 2011, this study also explored whether this finding was confirmed in a nationwide population.
Methods

Setting
We used two nationwide general practice databases for this retrospective population-based study: The Health Improvement Network (THIN, UK) and Health Search 
Participants
Individuals registered in both databases were considered eligible for inclusion if they were alive and had at least 1 year of database history available. The study period ranged from 1 January 2000 to 31 December 2012 in HSD-CSD-LPD and to 31 May 2012 in THIN, based on last data drawn at the time the study was conducted. Individual contribution to the cohort was censored at the end of the study period, transfer out of database or death, whichever came first. We identified eligible patients from both databases who were aged C65 years and had a diagnosis of dementia (Appendix 2). We also identified individuals aged \65 years and those aged C65 years, irrespective of dementia diagnosis, to allow a broad comparison of crude prevalence of AP use in these two populations with respect to those aged C65 years with dementia. We also hypothesised that more marked change in drug utilisation among individuals aged C65 years with dementia compared with the other two populations would suggest whether the safety warnings were specific to the former population.
Drug Exposure
AP prescriptions were identified using specific Multilex/ BNF codes in THIN (Appendix 3) and ATC codes (N05A*, except for lithium: N05AN*) in HSD-CSD-LPD. APs were grouped by therapeutic class: (1) atypical APs (amisulpride, aripiprazole, asenapine, clozapine, olanzapine, paliperidone, quetiapine, risperidone, sertindole, zotepine); (2) conventional APs (all other APs). We also individually analysed prescribing patterns for the most commonly prescribed APs (quetiapine, risperidone, olanzapine and haloperidol).
Statistical Analysis
To assess the effect of safety warnings on the prevalence of AP use, we used generalized linear models (GLMs) for longitudinal data, as they account for the effect of multiple measures over time collected by the same individual (cluster-level covariate) using the logit formula (specifically, the link function) and assuming a binomial distribution with first-order autoregressive covariance structure as regards subject error term. We used GLMs to model the probability of receiving an AP and included the time covariate as the main exposure. To account for the hierarchical data structure, we used a generalized estimating equation to calculate the parameters of GLMs and provide model-based robust standard errors. We conducted two main evaluations using GLMs: (1) whether the mean prevalence of AP use changed 3, 6 and 12 months before and after the warnings (i.e. to assess whether the onset of the warning effect was immediate and whether the effect persisted); (2) whether the prevalence of AP use changed over each unitary increase of a quarter year, performing a test for linear trends within each time interval between two consecutive safety warnings. For instance, using THIN data, four possible time intervals can be defined: (1) To assess the change in mean prevalence of AP use before and after the warnings, we built separate GLMs (overall, within each AP drug class for the most commonly used APs). These GLMs included an intercept term (this quantifies the logit of the estimated overall mean AP prevalence) and a categorical time variable where categories were ordered and defined according to the corresponding quarter year from the beginning to the end of the study (e.g. for THIN data, the time variable assumed value 0 for the first quarter of 2000, the value of 1 for the second quarter of 2000, and so on, until the end of the study). Comparisons between the estimated means of AP prevalence of use before and after each warning were statistically assessed using suitable comparisons (i.e. statistical contrasts), within the estimated GLMs, with respect to the quarter year at which each warning occurred (i.e. setting null coefficients for time points that must be ignored and setting contrasting non-null coefficients, with opposite sign and sum of zero, for all time points involved in the comparison with respect to the time point at which each warning occurred).
To evaluate whether the prevalence of AP use changed with every passing quarter year, we ran separate GLMs that included the presence of an individual in a specific time interval as a dummy covariate (e.g. three possible dummies if four time intervals are considered), the time covariate (i.e. the slope of the GLM, treated as continuous variable) and lastly, time-by-interval interaction terms. The person's presence in both databases was defined as the time between the person's registration in the database and their date of transfer out of the database, death or-if neither of these dates were registered-the end of the study. For each unitary increase of a quarter year, we estimated the mean change in the log odds of AP use (i.e. log odds ratio) within each time interval between the warnings using the time-byinterval interaction terms. We identified the presence of linear trends by testing the statistical significance of the log odds ratios. As a continuous time covariate and the interaction terms were included, this model successfully mimicked a segmented regression analysis using longitudinal data, as different slopes were estimated with respect to each specific time interval, the start of which was marked by the launch of a warning.
Furthermore, to assess how much the expected prevalence of AP use changed in absolute terms within each defined time interval, we adopted the following approach: (1) we derived the expected prevalence of AP use from GLMs for each quarter year using the inverse formula of the logit link function; (2) we calculated the absolute difference of expected prevalence between two consecutive quarters within each defined time interval; (3) we estimated the median (along with the 2.5 and 97.5 percentiles) of the distribution of all such differences, i.e. the slope representing the quarterly prevalence of AP use from the beginning to the end of one time interval. This information complements that provided by the previously defined GLMs and may be more easily interpreted. As the corresponding 2.5 and 97.5 percentiles of the medians cannot formally represent a 95 % confidence interval, we deduced their statistical significance from the corresponding log odds ratio. We further reported plots of the observed and estimated quarterly prevalence of AP use over time.
Finally, to put the above findings in a broader context, we calculated the annual prevalence rate of AP use in the time interval between one warning and another by (1) summing all patients' follow-up time (this represents the denominator in terms of person-years); (2) estimating the expected number of AP users (i.e. the numerator) by summing each persons' AP exposure time and dividing this by the person's total follow-up time for the whole population; and (3) dividing the numerator by the denominator.
Sub-Analysis
We identified individuals aged C80 years irrespective of a dementia diagnosis for a post hoc descriptive analysis to compare the prevalence of AP use between the oldest old in the Italian and UK populations. AP use is very likely to be related to dementia even in the absence of a dementia diagnosis in this population. In addition, these patients are likely to have more severe dementia than their younger counterparts, triggering more AP prescribing. Given these two assumptions, we hypothesised that a comparison of the prevalence of AP use in patients aged C80 years in the Italian and UK databases could indicate whether there was a differential use of these drugs that could partly explain significant differences in drug utilisation patterns in the two countries.
A p value \0.05 was considered statistically significant. All statistical analyses were performed using SAS Release 9.3 (SAS Institute, Cary, NC, USA).
Ethical Approval
The use of THIN and HSD-CSD-LPD for this study was approved by the THIN Scientific Review Committee (ref: SRC 13-085) and the Ethical Committee of the University of Messina, respectively.
Results
We identified 58,497 and 10,857 persons with dementia aged C65 years in THIN and HSD-CSD-LPD, respectively. The sex distribution and mean age in the two databases was similar (Table 2) . The crude quarterly prevalence of AP use in patients aged \65 years throughout the study period was approximately 0.6 % in both countries (Appendices 4 and 5), increasing to approximately 2 % in the general population aged C65 years in both countries (Appendices 6 and 7).
The quarterly prevalence of AP use in older people with dementia was initially similar in both countries: approximately 7 % in 2000, followed by a comparable gradual increase up to around 10 % in 2004 (Fig. 1) . The effect of the safety warnings about AP use in dementia from 2004-2009 and 2009-2012 is described in more detail in the following sections.
Effects of the Safety Warnings on Antipsychotic (AP) Use in Older People with Dementia from 2004 to 2009
The warnings issued in 2004 in the UK and Italy were associated with a marked short-term reduction in the use of atypical APs (Fig. 2) . In the UK, the quarterly prevalence of the use of atypical APs decreased rapidly, from a pre-warning peak of 8-6 % within \1 year following the warning; in Italy, there was a similar pattern, with a decrease from 6 to 5 % over the subsequent year. In contrast, prescribing of conventional APs increased in both countries. The prevalence of conventional AP use in the UK increased from 3.5 % to almost 4.5 % within less than 1 year after the warning, and remained stable thereafter (Fig. 3) .
Italy experienced a more sustained increase in conventional AP use, from 6 % at the time of the warning to 10 % in 2009. The overall prevalence of AP use returned to prewarning levels by 2005 in Italy and by 2007 in the UK. AP use continued to increase in both countries until 2009, more markedly so in Italy (Fig. 1). 
Statistical Comparisons
The statistical comparison of the prevalence of AP use at 3, 6 and 12 months before and after the warnings allowed the identification of the onset of the warning effect (i.e. a decrease in the prevalence of AP use) and whether this was statistically significant (Tables 3 and 4) . At 3, 6 and 12 months after the warning in the UK, atypical AP use decreased from 7 to 6 % (p \ 0.001), whereas use of conventional APs increased significantly from 3 to 4 % (p \ 0.001). In Italy, the use of conventional APs increased at 3, 6 and, especially, 12 months after the warning (from 5.7 to 7.2 % at 12 months; p \ 0.001), whereas the use of atypical APs did not significantly decrease at any of the time points evaluated.
Effects of the Safety Warnings on AP Use in Older People with Dementia from 2009 to 2012
The use of APs among those aged C65 years with dementia was approximately 5 % higher in Italy than in the UK in 2009 (Fig. 1) . (Figs. 2, 3) . 
Statistical Comparisons
No significant changes were seen in the prevalence of AP use overall or by class within 6 months after the 2009 warning in the UK, although the use of atypical and conventional APs by class increased slightly within 1 year (p = 0.001 and 0.01, respectively) ( Table 3) . Overall use of APs and atypical APs increased slightly but significantly within 6 months after the warning in Italy. AP use overall also changed significantly 12 months after the warning, when the prevalence increased from 19 to 22 % (p \ 0.001) (Table 4) , as a result of an increase in use of both conventional (from 10 to 11 %) and atypical APs (from 10 to 13 %).
Prescribing Trend of Individual APs in Older
People with Dementia The analysis of estimated mean changes in the prevalence of AP use and annual prevalence of use after the warnings were issued confirmed all the above findings (Appendices 13-16).
Sub-Analyses
The results of the sub-analysis comparing AP use in patients aged C80 years showed a comparable use of APs in the UK and Italy. The use of conventional APs was initially more prevalent (3 and 2 % in the UK and Italy, respectively in 2000), whereas the use of atypical APs was much lower (\1 % in both countries in 2000). Thereafter, the use of both classes remained between 1 and 2 % in the UK and Italy (Appendix 17).
Discussion
To our knowledge, this is the first population-based, nationwide study to explore short-and long-term effects of the safety warnings on AP use in dementia from two European countries, Italy and the UK. The comparative pattern of change of AP use in dementia in both countries provides key insights. The initial EMA/MHRA warning regarding the risk of stroke and mortality associated with risperidone and olanzapine led to a significant short-term reduction in the use of atypical APs over 12 months but an increased use of conventional APs. By 2005, the use of APs was again increasing in the UK and more so in Italy. Although the safety warnings in 2009 had a limited immediate impact on AP prescribing, there was a sustained 25 % reduction in AP use between 2010 and 2012 in the UK (from a quarterly prevalence of 14 to 11 %), whereas a substantial increase in total AP use (to 32 % in 2012) was observed in Italy. The prolonged reduction of AP use after the 2009 warning in the UK and the divergent pattern of AP use between the UK and Italy suggests that, at a national level, the safety warning, along with independent policy initiatives and proactive strategies by entities such as the National Dementia Alliance, may exert a greater influence on curbing the use of APs in dementia than the safety warnings launched by regulatory agencies alone.
The elevated use of APs in dementia remains a concern in both countries and cannot be explained by changes in the yearly prevalence of dementia in persons aged C65 years (Appendices 18 and 19). Although present data support a significant reduction in the use of APs in people with dementia since 2009 in the UK, this reduction was 25 % rather than the 50 % presented in the DAP audit results [14] . Furthermore, the level of reduction in AP use is still considerably less than the target of a two-thirds reduction proposed in the Bannerjee report for the UK Department of Health [11] . Nevertheless, it is clear that the change in AP use in the UK is much more favorable than that seen over the last decade in Italy, where one in three people with dementia were still prescribed APs in 2012. This increased pattern of use in Italy is also consistent with reports from other European countries (Appendix 1), emphasizing the need for coordinated action at a national level to achieve sustained reductions in the use of APs in people with dementia. Reasons why the warnings appeared to be relatively more successful in reducing AP use in dementia in the UK can only be speculated but may be related to several factors, such as the mode of dissemination, directness of the appeal to appropriate healthcare professionals, the clarity and action-oriented nature of the directive and the clarity with which the risk in question was communicated. For example, the 2004 warning by the MHRA was clearly action-oriented, recommending immediate review of patients because of ''an important concern'' about the increased risk of stroke, and was sent to all healthcare professionals as an ''Urgent message'' encouraging them to spread the word. In Italy, on the other hand, the risk communication in 2004 was conveyed only through EMA and not via the national regulatory agency, AIFA. The first AIFA communication on the topic was issued a year later, in 2005, but the warning of drug-related risk as well as information on the associated pharmacovigilance project appeared to target mainly prescribers in specialist dementia centres rather than all prescribers potentially responsible for the care of patients with dementia. The other warning in Italy, the 2009 AIFA communication, was a reminder of the legal context of AP prescribing in dementia; it did not highlight a concrete drug safety risk associated with these drugs to encourage more cautious prescribing (e.g. increased risk of stroke) and was not action-oriented. Similarly, the 2009 MHRA warning was not action-oriented but was limited to advice on drug prescribing; in addition, it was not actively disseminated but was published on the MHRA website. Nevertheless, the combined effect of this relatively passive regulatory action, supplemented by other continued actions aiming to reduce the use of APs in dementia is likely to have led to a sustained reduction in the use of APs in dementia patients in the UK.
This study has several strengths. The databases we used allowed us to sample a large number of primary care patients that can be considered representative of the two national populations. In addition, both countries have a universal healthcare system, which further increases the comparability of findings in the two countries. We used GLMs to estimate the prevalence of AP use accounting for clustered data (i.e. multiple measures over time per individual), an approach similar to the interrupted timeseries analysis. GLMs have several advantages over timeseries analysis. For example, time-series analysis is limited with regards to data fitting and requires the assumption of the stationary condition of the stochastic process, whereas this assumption is not required for GLMs. Interrupted time-series analysis may also be reliable in predicting future observations, provided the model represents the stochastic process very well. However, GLMs can provide statistical evaluations based on robust statistical inference of comparisons between the prevalence of AP use in different time windows using statistical comparisons, whereas these evaluations are not possible using time-series analysis.
The present study also has various strengths over similar studies. Some published studies considered the effect of the safety warnings only on risperidone and olanzapine use [19] , whereas others did not analyse APs by class [19, 24] . In addition, other studies had a shorter observation period than the present study [19, 22, 23] , did not use nationwide data [19, 22] or did not consider haloperidol-the most commonly prescribed conventional AP-individually [18, 19, 24] .
A limitation of this study is that no information was available on AP dispensing in both countries [17, 18] . In Italy, the use of atypical APs may be partly under-estimated since prescription drugs may be made available directly from Italian National Health Service (NHS) hospitals, thus by-passing GPs. The AP prescribing patterns described in the present study mainly reflect GP prescribing to elderly persons living in the community setting rather than in nursing homes. Nevertheless, in THIN, we were able to trace the living arrangements of 3746 patients aged C65 years with dementia, of whom 3554 were living in nursing homes. No information on whether patients were living in a nursing home was found in HSD-CSD-LPD; however, given the structure of the Italian NHS, it is likely that GP prescribing in nursing homes is similarly partially covered in HSD-CSD-LPD. Another limitation is that the diagnoses of dementia as found in THIN and HSD-CSD-LPD were not validated in the present study. Nevertheless, the prevalence of dementia in THIN was found to be comparable with national estimates in the UK [31] . We did not test the validity of dementia diagnoses in either database in the present study.
It should also be noted that, in an observational study such as this, findings can point to an association but not to a causal link between changes in AP prescribing pattern and the safety warnings. The influence of other factors on AP prescribing apart from the warnings, such as the DAP audit or initiatives by the National Dementia Alliance in the UK, may have influenced prescribing activities. In addition, comparisons between the warning effects should consider the different content and different dissemination methods used; however, this cannot be taken into account in the statistical analysis used.
Conclusion
The initial warnings targeting the use of olanzapine and risperidone in older people with dementia generally reduced the prescribing of these drugs in the short term, but resulted in a shift towards the use of quetiapine and conventional APs. Although the warnings led to a decrease in overall AP use in more recent years in the UK, it was more modest than stipulated by the DAP audit. Nevertheless, this reduction suggests that the pressure exerted in the UK to decrease AP prescribing in dementia achieved a substantial impact as compared with Italy, where AP prescribing continued to increase over the period of the study.
Author Contributions The authors contributed to the present study as follows. Literature search: JS, JI, CB, SS; study design/writing of protocol: JS, AF, GT; data extraction/data management: JS, FG, AP; data analysis: AF, JS, FG; writing and revision of manuscript: JS, AF, FG, AP, CB, CC, SS, ES, GG, JI, CF, MM, MS, GT; conception of study: GT. GT has access to all the data in the study and takes responsibility for the integrity of the data and the accuracy of the data analysis.
Compliance with Ethical Standards
Funding This study was funded by the Italian Health Minister in the context of the Project ''GR-2009-1607316-Assessment of the Safety of Antipsychotic Drugs in Elderly with Dementia: An International, Population-Based Study Using Healthcare Databases''. The funder played no role in the study design, data collection and analysis, decision to publish or preparation of the manuscript.
Conflicts of interest JS, AF, FG, AP, CB, CC, SS, ES, GG, JI, CF, MM, MS and GT have no competing interests to declare directly related to the present study. CC has received consulting fees/honoraria from Bayer unrelated to this study. ES has received grants unrelated to this study, consulting fees/honoraria from Eli Lilly unrelated to this study, payment for lectures unrelated to the study and is a board member for Astra-Zeneca and Lundbeck. MM has received funding from Pfizer, Astra-Zeneca and the international Adverse Events Consortium for studies unrelated to this study. CB has received grants and personal fees from Arcadia, Lundbeck, Napp, Roche, Orion, Bial, Bristol Myer Squibb, Otusaka and Novartis unrelated to this study.
